Persistent Pulmonary Hypertension Among Infants Undergoing Therapeutic Hypothermia for Hypoxic Ischemic Encephalopathy: A Systematic Review and Meta-Analysis.

Ther Hypothermia Temp ManagAug 20, 2025 (epub)
Clinical ResearchPediatrics

Rashida Javed, Tim J Van Hasselt, Narasimha Rao et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined whether therapeutic hypothermia (TH), compared with no TH or usual care, was associated with persistent pulmonary hypertension (PPHN) in infants with moderate to severe hypoxic-ischemic encephalopathy. Seven randomized controlled trials, including 1006 infants, contributed to the meta-analysis. The pooled relative risk of PPHN with TH versus no TH was 1.13 (95% confidence interval 0.81 to 1.57), providing no evidence of an association. The review also assessed nine observational studies narratively and noted that PPHN occurred in both treatment groups.

Key findings

  • Across seven randomized trials involving 1006 infants, the relative risk of PPHN with TH versus no TH was 1.13 (95% confidence interval 0.81 to 1.57).
  • The review found no evidence of an association between TH and PPHN in infants with moderate to severe HIE.
  • The authors noted that a considerable number of infants developed PPHN in both TH and no-TH groups.

Why it matters

PPHN occurred in infants with moderate to severe HIE whether or not they received therapeutic hypothermia. The pooled trial evidence did not show an association with TH, but the outcome remains clinically relevant in this population. Awareness of its occurrence can support timely investigation and management, as the authors suggest.

What to keep in mind

The review noted risk of bias related to blinding participants in the included randomized trials. The meta-analysis included seven trials; observational studies were reviewed narratively rather than pooled.

Source

Published in Ther Hypothermia Temp Manag. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.